SEC Comment Letter 0000000000-24-012578 to Ernexa Therapeutics Inc. (ERNA)
Ernexa Therapeutics Inc.
Date: Nov. 13, 2024 · CIK: 0000748592 · Accession: 0000000000-24-012578
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283003
Letter
November 13, 2024 Sanjeev Luther President and Chief Executive Officer Eterna Therapeutics, Inc. 1035 Cambridge Street, Suite 18A Cambridge, MA 02141 Re:Eterna Therapeutics, Inc. Registration Statement on Form S-1 Filed November 5, 2024 File No. 333-283003 Dear Sanjeev Luther: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Edwin Astudillo, Esq.
Show Raw Text
November 13, 2024
Sanjeev Luther
President and Chief Executive Officer
Eterna Therapeutics, Inc.
1035 Cambridge Street, Suite 18A
Cambridge, MA 02141
Re:Eterna Therapeutics, Inc.
Registration Statement on Form S-1
Filed November 5, 2024
File No. 333-283003
Dear Sanjeev Luther:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Edwin Astudillo, Esq.